Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.48 |
| ▸ | HPGD | P15428 | 5/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | GLA | P06280 | 2/20 | 0.48 |
| ▸ | CASP1 | P29466 | 2/20 | 0.48 |
| ▸ | CASP7 | P55210 | 2/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | NQO2 | P16083 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL621294 | 0.86 | BTK (0.53) | HAVCR2ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL14472404 | 0.82 | HTT (0.51) | ALDH1A1KDM4EHPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL5777181 | 0.80 | KDM4E (0.49) | ALDH1A1KDM4EHPGDHSD17B10GLA | |
| SCHEMBL399518 | 0.80 | HPGD (0.55) | ALDH1A1KDM4EHPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL352547 | 0.80 | PDE10A (0.50) | ALDH1A1KDM4EHPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL29450068 | 0.80 | PDE10A (0.50) | ALDH1A1KDM4EHPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL797828 | 0.79 | MAOA (0.48) | HAVCR2ALDH1A1KDM4EHPGDHSD17B10 | |
| Hydrochloric Acid SCHEMBL11089525 | 0.79 | HPGD (0.53) | ALDH1A1KDM4EHPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL16621492 | 0.78 | HAVCR2 (0.47) | HAVCR2ALDH1A1KDM4EHSD17B10ACHE | |
| SCHEMBL618587 | 0.78 | BCHE (0.48) | HAVCR2SMN1; SMN2ACHETDP1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4343804-A | 4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds | A. H. ROBINS COMPANY, INC. (US) | 1982-08-10 | — | — | US | claimed |
| EP-2603098-B1 | METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER | FIRMENICH INCORPORATED (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20240109915-A1 | NOVEL ACC INHIBITORS | PFIZER INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-11339128-B2 | Substituted 4-amino-5-(cyclohexyloxy)quinoline-3-carboxylic acids as sweet flavor modifiers | FIRMENICH INCORPORATED (US) | 2022-05-24 | — | — | US | disclosed |
| CN-114082407-A | Synthetic method of high-salinity medium-fluorine-removal adsorbent | 江苏海普功能材料有限公司 | 2022-02-25 | — | — | CN | disclosed |
| US-11129397-B2 | Method of improving stability of sweet enhancer and composition containing stabilized sweet enhancer | FIREMENICH INCORPORATED (US) | 2021-09-28 | — | — | US | disclosed |
| EP-3538512-B1 | NEW ANTHELMINTIC QUINOLINE-3-CARBOXAMIDE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2021-06-16 | — | — | EP | disclosed |
| CN-106107406-B | Methods of improving the stability of sweetness enhancers and compositions comprising stable sweetness enhancers | 弗门尼舍公司 | 2020-06-09 | — | — | CN | disclosed |
| EP-2552207-B1 | SWEET FLAVOR MODIFIER | FIRMENICH INCORPORATED (US) | 2019-08-21 | — | — | EP | disclosed |
| US-20190208802-A1 | METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER | FIRMENICH INCORPORATED | 2019-07-11 | — | — | US | disclosed |
| US-6372740-B1 | NERVOUS SYSTEM DISORDERS, ANTIEPILEPTIC AGENTS AND ANTIDEPRESSANTS | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2002-04-16 | — | — | US | disclosed |
| CN-1284076-A | 2-aryl-8-oxodihydropurine derivatives, process for producting same, medicinal conty. same, and intermediates thereof | DAINIPPON PHARMACEUTICAL CO (JP) | 2001-02-14 | — | — | CN | disclosed |
| EP-1036794-A1 | 2-ARYL-8-OXODIHYDROPURINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, MEDICINAL COMPOSITIONS CONTAINING THE SAME, AND INTERMEDIATES THEREOF | Dainippon Pharmaceutical Co., Ltd. (JP) | 2000-09-20 | — | — | EP | disclosed |
| US-5972946-A | NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1999-10-26 | — | — | US | disclosed |
| CN-1186487-A | Acetamide derivatives, process for producing the same, and medicinal composition containing the same | DAINIPPON PHARMACEUTICAL CO (JP) | 1998-07-01 | — | — | CN | disclosed |
| EP-0826673-A1 | ACETAMIDE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL COMPOSITION CONTAINING THE SAME | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1998-03-04 | — | — | EP | disclosed |
| US-5362743-A | Aminoquinoline derivatives | PFIZER INC. (US) | 1994-11-08 | — | — | US | disclosed |
| US-4343804-A | 4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds | A. H. ROBINS COMPANY, INC. (US) | 1982-08-10 | — | — | US | disclosed |
| US-4343804-A | 4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds | A. H. ROBINS COMPANY, INC. (US) | 1982-08-10 | — | — | US | disclosed |
| US-4343804-A | 4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds | A. H. ROBINS COMPANY, INC. (US) | 1982-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339128-B2 | Substituted 4-amino-5-(cyclohexyloxy)quinoline-3-carboxylic acids as sweet flavor modifiers | TAS2R5, TAS2R4, TAS2R30 | HAVCR2 4789/4885ALDH1A1 964/4885KDM4E 1051/4885 |
| US-20240109915-A1 | NOVEL ACC INHIBITORS | CBR3, NAT1, ACACB | HAVCR2 2191/4885ALDH1A1 2330/4885KDM4E 4784/4885 |
| US-11129397-B2 | Method of improving stability of sweet enhancer and composition containing stabilized sweet enhancer | TFEB, TREH, SLC2A8 | HAVCR2 4729/4885ALDH1A1 3324/4885KDM4E 476/4885 |
| US-20190208802-A1 | METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER | TFEB, TREH, SLC2A8 | HAVCR2 4729/4885ALDH1A1 3324/4885KDM4E 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.